We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
Location: United States, Massachusetts, Woburn
Employees: 11-50
Total raised: $105M
Founded date: 2012
Investors 3
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | OrbiMed | orbimed.co... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.08.2021 | Series B | $60M | - |
| 05.01.2018 | Series A | $45M | - |
Mentions in press and media 16
| Date | Title | Description |
| 27.08.2021 | Daily funding roundup - August 26th, 2021 | Picsart has raised $130M; Neurogastrx landed $60M; Recuro Health secured $15M Picsart: Picsart is a San Francisco-based popular design and editing app. Picsart has raised $130 million in Series C funding led by Softbank Vision Fund 2. Other... |
| 26.08.2021 | Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market | Neurogastrx thinks its late-stage acid reflux drug and another midstage gastrointestinal treatment can beat out existing mainstay therapies and has convinced investors to pump $60 million to get the two hopefuls closer to the finish line. T... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders | Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Ca... |
| 26.08.2021 | Neurogastrx Secures $60M in Series B Financing | - |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders | - |
| 26.08.2021 | After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPO | Two years after snaring a $45 million Series A from a couple of top-flight investors, Neurogastrx was finally ready to put its lead molecule into the clinical trials when the world shut down in March 2020. The small, GI-fo... |
| 26.08.2021 | Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market | Neurogastrx thinks its late-stage acid reflux drug and another midstage gastrointestinal treatment can beat out existing mainstay therapies and has convinced investors to pump $60 million to get the two hopefuls closer to the finish line. T... |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders | - |
| 26.08.2021 | Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders | - |
| 08.06.2021 | Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S. |
Show more